Brought to you by 
Takeda San Diego re-acquires DPP4 rights
19 Jul 2021
Executive Summary
Takeda San Diego (formerly Syrrx, before its acquisition by Takeda Pharmaceutical in February 2005) has re-acquired worldwide development and marketing rights to the dipeptidyl peptidase IV (DPP4) inhibitors that it formerly shared with PPD under a 2003 agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com